Drug Combination Details
| General Information of the Combination (ID: C48068) | |||||
|---|---|---|---|---|---|
| Name | Apigenin NP Info | + | Abivertinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
B-cell lymphoma
[ICD-11: 2A86]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | U-2932 | CVCL_1896 | B-cell lymphoma | Homo sapiens | ||
| OCI-Ly10 | CVCL_8795 | B-cell lymphoma | Homo sapiens | |||
| Experimental
Result(s) |
Apigenin can synergize with Abivertinib in treating DLBCL visa synergistically inducing apoptosis and inhibiting the p-GS3K-beta and its downstream targets. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro. J Cancer. 2020 Feb 3;11(8):2123-2132. | |||
